CHOP and R-CHOP Therapeutic Responses in Non-Hodgkin Lymphoma Patients in Dr. Soetomo General Hospital Surabaya

Rina Syarifah Salma, Made Putra Sedana, S. Ugroseno Yudho

= http://dx.doi.org/10.20473/bhsj.v1i2.9244
Abstract views = 489 times | downloads = 730 times

Abstract


Introduction: Non-Hodgkin Lymphoma (NHL) is a group of lymphoid-derived malignant disease with heterogenic biological and clinical manifestations. For over 30 years, CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) has been the first choice of chemotherapy for aggressive NHL. Later in 1997 Rituximab as anti-CD20 monoclonal antibody was introduced and then combined with CHOP as R-CHOP. The objective of this study is to acknowledge the response of the CHOP and R-CHOP therapy in Non-Hodgkin Lymphoma patients at Dr. Soetomo General Hospital.

Methods: The design of this study was retrospective observational study using secondary data obtained from patient’s medical records from 2011 to 2015. The data selected from the medical records are the result of the therapy, as well as patient’s gender and age.

Results: The results of patients’ therapy were classified into four categories: The study showed that 51.28% patients had Complete Response, followed by Partial Response (28.21%), Progressive Disease (17.95%), and No Change (2.56%). Sample characteristics showed male patients in higher percentage (66.67%), and the majority of patients’ age between 51-60 years old (30.77%). The use of CHOP and R-CHOP regiment were 76.92% and 20,52% respectively.

Conclusion: Most of the patients had a complete response. The CHOP regiment is more commonly used in patients compared to R-CHOP.


Keywords


Lymphoma Non-Hodgkin; CHOP; RCHOP; Response of Therapy

Full Text:

PDF

References


Little R and Wilson W. Non-Hodgkin Lymphomas. In: Rodgers G and Young N, (eds.). Bethesda Handbook of Clinical Hematology. 3rd ed. Philadephia: Lippincott Williams & Wilkins, 2013, p. 275-6.

Clarke CA and Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer. 2002; 94: 2015-23.

Provan D, Singer R, Baglin T and Dokal I. Lymphoma. 2nd ed. Oxford: Oxford University Press, 2004.

Dalam PHOMIP. Penatalaksanaan Limfoma Non-Hodgkin. In: PERHOMPEDIN, (ed.). Jakarta: PERHOMPEDIN, 2010.

Skrabek P, Turner D and Seftel M. Epidemiology of non-Hodgkin lymphoma. Transfus Apher Sci. 2013; 49: 133-8.

Mulyono A, Putra Sedana M and Ashariati A. ASOSIASI CA 125 DENGAN RESPON TERAPI PADA PENDERITA LIMFOMA NON-HODGKIN AGRESIF YANG MENDAPAT KEMOTERAPI CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE (CHOP). J Intern Med. 2011; 12.

Hegele V, Stoll P, Wust D, et al. Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence? Int J Clin Pharm. 2013; 35: 513-9.

Boye J, Elter T and Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003; 14: 520-35.

van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006; 108: 3295-301.

Jaime-Perez JC, Gamboa-Alonso CM, Vazquez-Mellado de Larracoechea A, et al. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma. Arch Med Res. 2015; 46: 454-61.

Horesh N and Horowitz NA. Does Gender Matter in Non-Hodgkin Lymphoma? Differences in Epidemiology, Clinical Behavior, and Therapy. Rambam Maimonides Medical Journal. 2014; 5: e0038.

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61: 69-90.

Micheli A, Mariotto A, Giorgi Rossi A, Gatta G and Muti P. The prognostic role of gender in survival of adult cancer patients. Eur J Cancer. 1998; 34: 2271-8.

Zheng T, Mayne ST, Boyle P, Holford TR, Liu WL and Flannery J. Epidemiology of non-Hodgkin lymphoma in Connecticut. 1935-1988. Cancer. 1992; 70: 840-9.

Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD and Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006; 107: 265-76.

Nicolaides C, Dimou S and Pavlidisa N. Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas. Oncologist. 1998; 3: 189-97.

Carli PM, Coebergh JW and Verdecchia A. Variation in survival of adult patients with haematological malignancies in Europe since 1978. EUROCARE Working Group. Eur J Cancer. 1998; 34: 2253-63.

Vercelli M, Capocaccia R, Quaglia A, Casella C, Puppo A and Coebergh JW. Relative survival in elderly European cancer patients: evidence for health care inequalities. The EUROCARE Working Group. Crit Rev Oncol Hematol. 2000; 35: 161-79.

Maartense E, Kluin-Nelemans HC, le Cessie S, Kluin PM, Snijder S and Noordijk EM. Different age limits for elderly patients with indolent and aggressive non-hodgkin lymphoma and the role of relative survival with increasing age. Cancer. 2000; 89: 2667-76.


Refbacks

  • There are currently no refbacks.




Copyright (c) 2018 Biomolecular and Health Science Journal

INDEXING BY:

Creative Commons License

This Journal (E-ISSN:2620-8636) is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

View BHSJ Stats